10Mar, 14Press Release, Moscow, March 11th, 2014MAXWELL BIOTECH VENTURE FUND’S PORTFOLIO COMPANY HEPATERA COMPLETES ENROLLMENT OF PHASE IIA CLINICAL TRIAL OF...
13Apr, 19ILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with PEG-IFN-a in Phase 2b study involving individuals with chronic hepatitis B/D virus coinfection, producing high rates of viral suppression bILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with...
04Apr, 19MYR Pharmaceuticals Announces Presentation of Final Results of the MYR203 Study of bulevirtide (Myrcludex) at the International Liver Congress (ILC) 2019 in Vienna.MYR Pharmaceuticals today announced that the final results of the MYR203 study of bulevirtide (Myrcludex), MYR´s...
23Mar, 16Maxwell Biotech Venture Fund’s Portfolio Company Hepatera LLC Announces Start of Phase 2b clinical trial of Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic HBV and HDV InfectionHepatera LLC and it`s development partner MYR GmbH today announced the initiation of MYR 202, a Phase 2b open label,...
07Mar, 19MYR Pharmaceuticals Announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA for Bulevirtide (Myrcludex), the First-in-Class Entry Inhibitor for Treatment of Chronic Hepatitis D InfectionsMYR Pharmaceuticals announced today that the British Medicines and Healthcare products Regulatory Agency (MHRA) has...
